- Home
- LOB vs AMLX Comparison
LOB vs AMLX Comparison
Compare LOB & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LOB | AMLX |
|---|---|---|
| Founded | 2008 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.9B |
| IPO Year | 2014 | 2021 |
Fundamental Metrics
Financial Performance| Metric | LOB | AMLX |
|---|---|---|
| Price | $35.58 | $13.23 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $43.00 | $21.56 |
| AVG Volume (30 Days) | 177.2K | ★ 1.0M |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.32% | N/A |
| EPS Growth | 31.95 | ★ 65.46 |
| EPS | ★ 0.60 | N/A |
| Revenue | N/A | ★ $380,786,000.00 |
| Revenue This Year | $35.52 | N/A |
| Revenue Next Year | $16.03 | N/A |
| P/E Ratio | $60.08 | ★ N/A |
| Revenue Growth | N/A | ★ 1612.94 |
| 52 Week Low | $26.19 | $4.64 |
| 52 Week High | $42.89 | $18.61 |
Technical Indicators
Market Signals| Indicator | LOB | AMLX |
|---|---|---|
| Relative Strength Index (RSI) | 43.20 | 30.38 |
| Support Level | $34.12 | $12.29 |
| Resistance Level | $37.53 | $15.37 |
| Average True Range (ATR) | 0.87 | 0.83 |
| MACD | -0.31 | -0.37 |
| Stochastic Oscillator | 5.49 | 1.37 |
Price Performance
Historical ComparisonAbout LOB Live Oak Bancshares Inc.
Live Oak Bancshares Inc operates as the bank holding company for the Live Oak Banking Company. The company specializes in lending and deposit-related services to small businesses nationwide. The company identifies and extends lending to credit-worthy borrowers both within specific industries, also called verticals, through expertise within those industries, and more broadly to select borrowers outside of those industries. A portion of the loans originated by the Bank are partially guaranteed by the Small Business Administration under the 7(a) Loan Program and the U.S. Department of Agriculture Rural Energy for America Program, Water and Environmental Program, Business and Industry and Community Facilities loan programs.
About AMLX Amylyx Pharmaceuticals Inc.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.